Tyndall National Institute will lead a project to develop cutting edge heart monitoring technology that is currently not available to patients.
More than €4 million will be invested in a digital health project to bring a potentially lifesaving smart cardiac monitoring patch ‘SmartVista’ to life.
As lead partner, Tyndall National Institute will work with international partners to develop the wearable biosensor technology for real-time wireless monitoring of remote patients.
The SmartVista wearable biosensor will aim to deliver a seamless feed of patient data, particularly heart rhythm, respiration, temperature and oxygen flow.
“This is game changing technology in the digital health sector,” said Professor William Scanlon,CEO of Tyndall which has been awarded €1 million to lead the SmartVista project.
“Powered by body heat, the SmartVista patch will enable patients to live normal lives away from hospital or clinical environments, and yet be fully monitored in real time.
“The societal impact in terms of waiting times, hospital infrastructure and patient comfort and care is very significant,” he added.
The Smartvista system will be able to extract energy from the body to power itself.
Real-time information from the system will be be transmitted wirelessly for online health processing.
This real-time self-powered monitoring of a patient’s health in this manner is not currently available.
“Monitoring vital signs is key for patient health and well being; the SmartVista technology will revolutionise patient care enabling remote, real time monitoring,” said project lead, Tyndall’s Dr Kafil M. Razeeb.
“The latest nano and energy research from partners across the EU will combine at Tyndall National Institute, and this multi million euro investment will be strategically deployed to deliver a new digital health patch application which will have global applicability.” Funding for SmartVista has been provided through the EU Horizon 2018-2020 ICT programme.